Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
复制标题
DOI：
10.1016/j.jhep.2013.07.017
复制
发表时间：
2013-12-01
影响因子：
25.7
通讯作者：
Bonino, Ferruccio
中科院分区：
文献类型：
--
作者：
Brunetto, Maurizia R.;Marcellin, Patrick;Bonino, Ferruccio
背景与目的：在III期试验中，我们研究了HBV基因型是否影响hbeag阴性慢性乙型肝炎患者接受聚乙二醇干扰素α -2a +/-拉米夫定治疗时HBsAg动力学和/或治疗结束时HBsAg水平与长期病毒学反应相关。方法：所有参与长期随访的患者（n = 230）根据HBsAg水平测量的可用性纳入。长期病毒学反应定义为HBV DNA
Background & Aims: We investigated whether HBV genotype influences on-treatment HBsAg kinetics and/or the end-of-treatment HBsAg levels associated with long-term virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a +/- lamivudine in the Phase III trial.Methods: All patients (n = 230) who participated in long-term follow-up were included according to the availability of HBsAg level measurements. Long-term virological response was defined as HBV DNA